Commercial challenges of protein drug delivery

Expert Opinion on Drug Delivery

Volumn 2, Issue 1, 2005, Pages 29-42

  Brown, Larry R ^a,b  

^a Baxter Healthcare Corporation   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Biotechnology; Drug delivery; Insulin; Microsphere; Nasal; Oral; Peptide; PLGA; Polyethylene glycol; Protein; Pulmonary

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA2A INTERFERON; ASPARAGINASE MACROGOL; CYCLOSPORIN; DESMOPRESSIN; GLATIRAMER; GLYCOLIC ACID; GONADORELIN AGONIST; GOSERELIN; HUMAN GROWTH HORMONE; INFLIXIMAB; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LACTIC ACID; NAFARELIN ACETATE; OCTREOTIDE; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT PROTEIN; RITUXIMAB; SALCATONIN; SOMATOSTATIN; SUPEROXIDE DISMUTASE MACROGOL; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; BURNING SENSATION; CARCINOID; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CROHN DISEASE; DIABETES INSIPIDUS; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDICATION; DRUG MANUFACTURE; DRUG PENETRATION; DRUG POTENTIATION; DRUG STABILITY; DRUG TARGETING; EMPHYSEMA; ENDOMETRIOSIS; ERYTHEMA; FEBRILE NEUTROPENIA; GRAFT REJECTION; GROWTH HORMONE DEFICIENCY; HEPATITIS C; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; LIPOATROPHY; LIVER CIRRHOSIS; NEEDLE; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPOROSIS; PROSTATE CANCER; PRURITUS; PSORIASIS; RECOMBINANT DNA TECHNOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SKIN BRUISING; SUSTAINED RELEASE FORMULATION; SYRINGE; SYSTEMATIC REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HALF-LIFE; HUMANS; PROTEINS; RECOMBINANT PROTEINS;

EID: 12344281758     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.1.29     Document Type: Review

References (69)

1. Tractatus de corde item de motu et colore sanguinis et chyli in eum transitu (1669); facs. repr. with English trans. In: R.T. Gunther, Early Science in Oxford. Oxford (1932)9.
2. BLUNDELL J: Successful case of transfusion. Lancet (1829) 1:431-432.
3. BLOOM AL: The evolution and future of haemophilia therapy. Transfus. Med. (1991) 1(1):5-12.
4. BAZIN H: The eradication of smallpox: Edward Jenner and the first and only eradication of a human infectious disease. Academic Press, San Diego (2000).
5. BANTING FG, BEST CH: The internal secretion of the pancreas. J. Lab. Clin. Med. (1922) 8(5):1-16.
6. JENSEN HF: Insulin, its chemistry and physiology. Oxford University Press, New York (1938) 92-112.
7. LEWIS J: Insulin administration problem. Physiol. Rev. (1949) 29:75.
8. HAGEDOR HC, JENSEN BN, KRARUP BN, WODSTRUP K: Protamine insulinate. JAMA (1936) 106:177.
9. SCOTT D, FISHER AJ: Prolongation of insulin action by protamine and zinc. J. Biol. Chem. Sc. Proc. (1936) 114:88.
10. HALLAS-MOLLER K, JERSILD M, PETERSON K: Insulin preparations for single daily injection, clinical studies of new preparations with prolonged action. JAMA (1952) 150:1667.
11. MORROW JF, COHEN SN, CHANG AC et al.: Replication and transcription of eukaryotic DNA in Escherichia coli. Proc. Natl. Acad. Sci. USA (1974) 71:1743-1747.
12. ITAKURA K, HIROSE T, CREA R et al.: Expression in escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science (1977) 9:198(4321):1056-1063.
13. The therapeutic proteins outlook to 2007: an analysis of leading products and late-stage pipeline developments. Reuters Business Insight, Aug (2003).
14. LEICHTER SB: The business of insulin: a relationship between innovation and economics. Clin. Diabetes (2003) 21:40-42.
15. Med. Ad. News, May (2004) 23(5):70-72.
16. SHAH RB, AHSAN F, KHAN MA: Oral delivery of proteins: progress and prognostication.Crit. Rev. Ther. Drug Carrier Sys. (2002) 19:135-169.
17. VIDEX EC: 125mg, 200mg, 250mg and 400mg Gastro-resistant, Capsules Bristol-Myers Squibb Pharmaceuticals Ltd, Hounslow, UK May (2004).
18. JOSLIN EP, GRAY H, ROOT HF: Insulin in and home. J. Metab. Res. (1922) 2:651.
19. CLEMENT S, DANDONA P, GORDON STILL J, KOSUTIC G: Oral modified insulin (HIM2) in patients with Type 1 diabetes mellitus: results from a Phase I/II clinical trial. Metab. (2004) 53 54-58.
20. DDAVP Tablets Package Insert, Aventis Pharmaceuticals. Inc., Bridgewater, NJ 08807 USA Rev. November 2002.
21. VILHARDT H, LUNDIN S, FALCH J: Plasma kinetics of DDAVP in man. Acta Pharmacol. Toxicol. (1986) 58: 379-381.
22. SACHDEVA A, GULATI R, GUPTA U, BAPNA JS: Comparative bioavailability of two brands of cyclosporinee. Indian J. Pharm. (1997) 29:135-137.
23. HOLT DW, MUELLER EA, KOVARIK JM ET AL.: Sandimmune® Neoralo® pharmacokinetics: impact of the new oral formulation. Transplant Proc. (1995) 27(1):1434-1447.
24. CASEZ JP, TSCHOPP P SANDBERG TSCHOPP A, LIPPUNER K, ZINGG E, JAEGER P: Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism. Horm. Res. (2003) 59:263-269.
25. CRANNEY A, TUGWELL P, ZYTARUK N et al.: Osteoporosis methodology group and the osteoporosis research advisory group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23(4):540-551.
26. PONTIROLI AE, ALBERETTO M, CALDERARA A, PAJETTA E, POZZA G: Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents. Eur. J. Clin. Pharmacol. (1989) 37 4):427-430.
27. CHAPLIN MD: Bioavailability of nafarelin in healthy volunteers. Am. J. Obstet. Gynecol. (1992) 166(2):762-765.
28. FEBER J, COCHAT P, HADJ-AISSA A, DUBOURG L, WRIGHT C, POZET N: Renal concentrating capacity test by desmopressin in children: intranasal or intravenous route? Am. J. Nephrol. (1993) 13 2):129-131.
29. LAURSEN T, GRANDJEAN B, JORGENSEN JO, CHRISTIANSEN JS: Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration. Eur. J. Endocrinol. (1996) 135(3):309-315.
30. VALENSI P, ZIRINIS P, NICOLAS P, PERRET G, SANDRE-BANON D, ATTALI JR: Effect of insulin concentration on bioavailability during nasal spray administration. Pathol. Biol. Paris (1996) 44 4):235-240.
31. HILSTED J, MADSBAD S, HVIDBERG A et al.: Intranasal insulin therapy: the clinical realities. Diabetologia (1995) 38 6):680-684.
32. GANSSLEN M: Uber Inhalation von Insulin. Klin. Wchnschr. (1925) 4:71.
33. PATTON JS, BUKAR J, NAGARAJAN S: Inhaled insulin. Adv. Drug Del. Rev. (1999) 35:235-247.
34. SKYLER JS, CEFALU WT, KOURIDES LA et al.: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 357:331-335.
35. OWENS DR, ZINMAN B, BOLLI G: Diabet. Med. (2003) 20 886-898.
36. BROWN LR, JARPE M, MCGEEHAN J, QIN Y, MOORE E, HOGELAND K: Resp. Drug Del. IX. (2004) 2:477-480.
37. SELAM JL: Insuline inhalée: résultats cliniques chez le diabétique de Type 2. Diabetes Metab. (2001) 27:S28-S32.
38. BITONTI AJ, DUMONT JA, LOW SC et al.: Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA (2004) 101:9763-9768.
39. CEFALU, WT: Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care (2004) 27 1):239-246.
40. BROWN L, MUNOZ C, SIEMER L, EDELMAN E, LANGER R. Controlled release of insulin from polymer matrices: control of diabetes in rats. Diabetes (1986) 35(6):692-696.
41. KNOBIL, E. The GnRH pulse generator. Am. J. Obstet. Gynecol. (1990) 163:1721-1727.
42. R&D Directorate Report No. 54. Goserelin or other gonadotrophin releasing hormone (GnRH) analogues in the treatment of advanced prostate cancer. NHS Executive South and West, Report to the Development and Evaluation Committee. (1996) 13.
43. OKADA H: One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Del. Rev. (1997) 28(1):43-70.
44. SARTOR O, DINEEN MK, PEREZ-MARRENO R, CHU FM, CARRON GJ, TYLER RC: An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. (2003) 62:319-323.
45. SCOTT T, BLIZZARD C, BROWN L, RASHBA-STEP J, WAGNER L, RISKE F: Extended Release ProMaxx™ LH-RH Analog Microspheres. Proceedings of the International Symposium on the Controlled Release of Bioactive Materials (1999) 26.
46. LANCRANJAN I, BRUNS C, GRASS P, JAQUET J et al.: Sandostatin LARÒ: pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromeglic patients. Metabolism (1995) 44 18-26.
47. SCARPIGNATO C, PELOSINI I, S: Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy (2001) 47 2):1-29.
48. WARNER B, WORGUL TJ, DRAGO J et al.: Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J. Clin. Invest. (1983) 71(6):1842-1853.
49. DONG HN, YU SY, SNG DL et al.: Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. J. Contr. Rel. (2003) 92 3):291-299.
50. JOHNSON OL, CLELAND JL, LEE HJ et al.: A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. (1996) 7:795-799.
51. BERKLAND C, KING M, COX A: Precise control of PLG microsphere size provides enhanced control of drug release rates. J. Contr. Rel. (2002) 82:137-147.
52. Nutropin Depot ® [somatropin(rDNAorigin)forinjectablesuspensi on] and diluent for nutropin depot package insert. Genentech, Inc. April (2002).
53. KOZLOWSKI A, HARRIS JM: Improvements in protein Pegylation: pegylated interferons for treatment of hepatitis C. J. Contr. Rel. (2001) 72:217-224.
54. VERONESE FM: Peptide and protein Pegylation: a review of problems and solutions. Biomaterials (2001) 22(5):405-417.
55. HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New Engl. J. Med. (2000) 343:1673-1680.
56. OVERBAY DK, MANLEY HJ: Darbepoetin-alpha: a review of the literature. Pharmacotherapy (2002) 22(7): 889-897.
57. BROWN LR: Glucose-mediated insulin delivery from implantable polymers. In: Polymeric biomaterials. Dumitriu S (Ed.) Marcel Dekker, Inc, New York (2002) 1101-1115.
58. DEFELIPPIS MR, BAKAYSA M, BELL A et al.: Preparation and characterization of cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. J. Pharm. Sci. (1998) 87:170-176.
59. HOME PD, BARRIOCANAL L, LINDHOLM A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. (1999) 55:199-203.
60. GILLIES PS, FIGGITT DP, LAMB HM: Insulin glargine. Drugs (2000) 59:253-260.
61. LUZIO SD, BECK P, OWENS DR: Horm. Metab. Res. (2003) 35(7):434-438.
62. WOOD A: New methods of treating neuralgia by the direct of opiates to the painful points. Edinburgh Med. Surg. J. (1855) 16 265-281.
63. HOWARD-JONES N: The origins of hypodermic medication. Sci. Am. (1971) 224:96-102.
64. LEE DM: How painful is intensive insulin therapy? Z. Gesamte Inn. Med. (1992) 47:266-269.
65. SILVERSTEIN JH, MURRAY FT, MALASANOS T, MYERS S, JOHNSON SB, GROSSMAN M: Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children. Endocrine (2001) 15:15-17.
66. ROY N, AGARWAL S: Therapeutic protein production -an overview. Business Briefing: Future Drug Discovery (2003) 79-82.
67. PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. (1999) 340(18):1398-1405.
68. VOSE JM, LINK BK, GROSSBARD ML, et al.: Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkids Lymphoma. J. Clin. Oncol. (2001) 15:389-397.
69. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.